2017 年 36 巻 5 号 p. 41-48
Background: Undifferentiated pleomorphic sarcoma (UPS) is an aggressive mesenchymal malignancy. Although patient-derived cell lines are invaluable tools for preclinical studies, there are only a few UPS cell lines available in public cell banks. In the present study, we established a cell line from the primary tumor tissue of a UPS patient. Methods: Primary UPS tumor tissues were sampled to establish cell lines. Morphological and proteomic analyses were performed and sensitivity to anti-cancer drugs was evaluated. Results: We established a novel UPS cell line, namely NCC-UPS1-C1 cells, and maintained the cells for over 100 passages. The characters of cells as morphology, growth rate, colony formation capacity, and immune-histochemical traits were confirmed. Mass spectrometric protein expression profiling revealed that the proteome of the original tumor tissue differed from that of the cell line. Sensitivity to 164 anti-cancer drugs was screened for their growth inhibitory effects. Conclusions: Patient-derived cell line in this study may be useful for understanding the molecular background of drug resistance in UPS. Furthermore, the use of the patient-derived cancer model will facilitate our understanding of molecular mechanisms underlying poor prognosis, and will contribute to novel therapeutic strategies.
